AstraZeneca: clinical trial fails for cediranib
(CercleFinance.com) - On Thursday AstraZeneca and its American partner Merck announced the failure of a clinical trial of cediranib in the treatment of ovarian cancer.
The phase III study, whose two groups unveiled the conclusions this morning, "did not meet the primary endpoint of progression-free survival," they explained.
The trials were designed to compare the efficacy of an association between cediranib and Lynparza, their lead anticancer agent, compared to simple chemotherapy.
Ovarian cancer is the eighth most fatal cancer affecting women worldwide.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The phase III study, whose two groups unveiled the conclusions this morning, "did not meet the primary endpoint of progression-free survival," they explained.
The trials were designed to compare the efficacy of an association between cediranib and Lynparza, their lead anticancer agent, compared to simple chemotherapy.
Ovarian cancer is the eighth most fatal cancer affecting women worldwide.
Copyright (c) 2020 CercleFinance.com. All rights reserved.